Synthekine
About Synthekine
Synthekine is developing selective cytokine therapies using cytokine partial agonists, orthogonal cytokine and cell therapies, and surrogate cytokine agonists to enhance treatment efficacy for cancer and autoimmune diseases. The company addresses the limitations of current cytokine therapeutics by engineering solutions that minimize pleiotropy and improve therapeutic specificity.
```xml <problem> Traditional cytokine therapies often suffer from pleiotropic effects, leading to broad and systemic immune activation, which can result in toxicity and reduced therapeutic efficacy. The lack of specificity in current cytokine treatments limits their ability to selectively target and modulate the immune response in cancer and autoimmune diseases. </problem> <solution> Synthekine is developing a new generation of selective cytokine therapies designed to overcome the limitations of traditional approaches. Their technology focuses on engineering cytokine partial agonists, orthogonal cytokine and cell therapies, and surrogate cytokine agonists to enhance treatment efficacy and minimize off-target effects. By creating more selective immunotherapies, Synthekine aims to precisely modulate the immune system, improving outcomes for patients with cancer and autoimmune/inflammatory diseases while reducing adverse events. This targeted approach allows for a more controlled and effective immune response, maximizing therapeutic benefits. </solution> <features> - Cytokine partial agonists that selectively activate specific signaling pathways, reducing pleiotropy. - Orthogonal cytokine and cell therapies designed to enhance the specificity and efficacy of cell-based immunotherapies. - Surrogate cytokine agonists that mimic the activity of natural cytokines with improved pharmacological properties. - A proprietary platform for engineering and optimizing cytokine therapeutics. - Development of a broad pipeline of selective immunotherapies targeting a range of cancers and autoimmune/inflammatory diseases. </features> <target_audience> The primary target audience includes patients with cancer and autoimmune/inflammatory diseases who could benefit from more selective and effective immunotherapies, as well as clinicians and researchers in the fields of oncology and immunology. </target_audience> ```
What does Synthekine do?
Synthekine is developing selective cytokine therapies using cytokine partial agonists, orthogonal cytokine and cell therapies, and surrogate cytokine agonists to enhance treatment efficacy for cancer and autoimmune diseases. The company addresses the limitations of current cytokine therapeutics by engineering solutions that minimize pleiotropy and improve therapeutic specificity.
Where is Synthekine located?
Synthekine is based in Menlo Park, United States.
When was Synthekine founded?
Synthekine was founded in 2018.
How much funding has Synthekine raised?
Synthekine has raised 288610000.
- Location
- Menlo Park, United States
- Founded
- 2018
- Funding
- 288610000
- Employees
- 98 employees
- Major Investors
- The Column Group